Immunomodulatory effects of lenvatinib plus anti–programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma L Torrens, C Montironi, M Puigvehí, A Mesropian, J Leslie, PK Haber, ... Hepatology 74 (5), 2652-2669, 2021 | 92 | 2021 |
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications J Carrillo-Reixach, L Torrens, M Simon-Coma, L Royo, M Domingo-Sàbat, ... Journal of hepatology 73 (2), 328-341, 2020 | 85 | 2020 |
Liver injury increases the incidence of HCC following AAV gene therapy in mice DA Dalwadi, L Torrens, J Abril-Fornaguera, R Pinyol, C Willoughby, ... Molecular Therapy 29 (2), 680-690, 2021 | 70 | 2021 |
Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma R Esteban-Fabró, CE Willoughby, M Piqué-Gili, C Montironi, ... Clinical Cancer Research 28 (11), 2449-2460, 2022 | 41 | 2022 |
Metabolic Landscape of the Mouse Liver by Quantitative 31P Nuclear Magnetic Resonance Analysis of the Phosphorome G Bernardo‐Seisdedos, J Bilbao, D Fernández‐Ramos, F Lopitz‐Otsoa, ... Hepatology 74 (1), 148-163, 2021 | 16 | 2021 |
Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma. L Torrens, C Montironi, M Puigvehí, A Mesropian, J Leslie, PK Haber, ... Hepatology, 2021, vol. 74, num. 5, p. 2652-2669, 2021 | 15 | 2021 |
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma J Abril-Fornaguera, L Torrens, C Andreu-Oller, J Carrillo-Reixach, ... Molecular cancer therapeutics 22 (4), 485-498, 2023 | 5 | 2023 |
Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma R Esteban-Fabró, CE Willoughby, M Piqué-Gili, J Peix, C Montironi, ... Journal of Hepatology 73, S40, 2020 | 5 | 2020 |
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma A Rialdi, M Duffy, AP Scopton, F Fonseca, JN Zhao, M Schwarz, ... Nature Cancer 4 (8), 1157-1175, 2023 | 2 | 2023 |
PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, M Pique-Gili, R Esteban-Fabro, G Philips, R Pinyol, ... HEPATOLOGY 78, S1871-S1872, 2023 | | 2023 |
Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures S Cappuyns, M Piqué-Gili, R Esteban-Fabró, G Philips, R Pinyol, ... Journal of Hepatology 78, S52-S53, 2023 | | 2023 |
TRANSLATING SINGLE-CELL TO BULK RNA SEQUENCING DATA TO IDENTIFY RESPONDERS TO CHECKPOINT INHIBITION IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, R Esteban-Fabro, G Philips, V Vandecaveye, M Pique-Gili, ... Hepatology 76, S1275-S1276, 2022 | | 2022 |
PMEPA1 has an oncogenic role in hepatocellular carcinoma in the context of TGFβ signaling: data from single cell RNAseq and transgenic models R Pinyol, C Andreu-Oller, M Piqué-Gili, R Esteban-Fabró, ... European Journal of Cancer 174, S120, 2022 | | 2022 |
Computational identification of targetable dependencies in hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) replication M Pique-Gili, C Andreu-Oller, R Pinyol, R Esteban, M Barcena-Varela, ... CLINICAL CANCER RESEARCH 28 (17), 2022 | | 2022 |
Abstract PR02: PMEPA1 has an oncogenic role in the context of TGF-β signaling in hepatocellular carcinoma M Pique-Gili, C Andreu-Oller, R Pinyol, R Esteban, M Barcena-Varela, ... Clinical Cancer Research 28 (17_Supplement), PR02-PR02, 2022 | | 2022 |
Abstract PO009: Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma J Abril-Fornaguera, L Torrens, J Carrillo-Reixach, A Rialdi, ... Clinical Cancer Research 28 (17_Supplement), PO009-PO009, 2022 | | 2022 |
PMEPA1 is an oncogene linked to TGF-β signaling in hepatocellular carcinoma M Pique-Gili, C Andreu-Oller, R Pinyol, M Bárcena-Varela, ... Cancer Research 82 (12_Supplement), 840-840, 2022 | | 2022 |
Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma L Torrens, J Abril-Fornaguera, J Carrillo, U Balaseviciute, A Rialdi, ... JOURNAL OF HEPATOLOGY 75, S240-S241, 2021 | | 2021 |
CABOZANTINIB ENHANCES THE EFFICACY AND IMMUNE MODULATORY ACTIVITY OF ANTI-PD1 TREATMENT IN A SYNGENEIC MOUSE MODEL OF HCC R Esteban-Fabro, CE Willoughby, M Pique-Gili, J Peix, J Abril-Fornaguera, ... HEPATOLOGY 70, 1201A-1202A, 2019 | | 2019 |